Trial NCT04715295
Publication Sobngwi E, medRxiv, 2021 (preprint)
Dates: 2021-03-16 to 2021-04-09
Funding: Public/non profit (Partially sponsored by a special grant from the French Embassy in Cameroon. )
Conflict of interest: No
| Methods | |
| RCT Blinding: Unblinded | |
| Location :
Single center / Cameroon Follow-up duration (days): 30 | |
| Inclusion criteria | 18 years of age or older; COVID-19 infection confirmed by RT-PCR; asymptomatic or with mild symptoms; SpO2 > 94 % |
| Exclusion criteria | Pregnant, breast-feeding; currently taken trial study medication; any contraindication to study medication; severe cardiac disease; renal or liver insufficiency, respiratory rate ≥ 30/min, BP > 90/60 mmHg. |
| Interventions | |
| Treatment
Doxycycline 100 mg orally twice a day for 7 days |
|
| Control
Hydroxychloroquine + Azithromycin ( / ) | |
| Participants | |
| Randomized 194 participants (n1=97 / n2= 97) | |
| Characteristics of participants N=194 Mean age : 38.5 98 males Severity : Mild: n=0 / Moderate: n=0/ Severe: n=0 Critical: n=0 | |
| Primary outcome | |
| In the register Clinical: Change of Clinical stage of COVID-19; Virological: Time to negativity of SARS-CoV-2 reverse transcription-polymerase chain reaction (RT-PCR) on nasopharyngeal swab. [ Time Frame: Day 1 to 10 ] | |
| In the report Clinical cure rate defined as the proportion of participants becoming or remaining asymptomatic | |
| Documents available |
Protocol NR Statistical plan NR Data-sharing stated
|
| Risk of bias Overall The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review |
|
| General comment |